Press Releases

JERUSALEM, Dec. 3, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that the Company has entered into an Ordinary Shares Purchase Agreement for $10.0 million with Aspire Capital Fund, LLC ("Aspire Capital"), a Chicago-based inst

CALGARY, Dec. 3, 2019 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (CSE: WLLW; OTCQB: CANSF), a Canadian biotechnology company and a leading developer in biosynthetically produced cannabidiol ("CBD"), comments on Purisys, LLC's ("Purisys") news release issued on November 21st

FREMONT, Calif., Dec. 3, 2019 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with cardiorenal diseases, today reported positive topline results from PHREEDOM, a long-term Phase 3 study evaluating the efficacy and safety of tenapanor as monotherapy fo

HONG KONG and SHANGHAI, Dec. 3, 2019 /PRNewswire/ -- Ping An Insurance (Group) Company of China, Ltd. (hereafter "Ping An" or the "Group", HKEx:2318; SSE:601318) has received two awards at the Directors Of The Year Awards 2019, organized by the Hong Kong Institute of Director

CLEVELAND, Dec. 3, 2019 /PRNewswire/ -- Children are once again standing in line at shopping centers across America for a chance to plead their case for presents directly with Santa himself. For the thousands who dress up and stand in for Santa every season, it's inspiring to provide children with a magical experience. However, there is a downside. Li

CHARLOTTE, N.C., Dec. 3, 2019 /PRNewswire/ -- An alarming report recently published by The Washing

CAMPBELL, Calif., Dec. 3, 2019 /PRNewswire/ -- Adona Medical, a newly formed Shifamed portfolio company, announced today the closing of its seed financing round, raising a total of $2.5M. The financing, raised exclusively from select Shifamed accredited Angel Investors, will be used to advance product development and expand the company'

NEWARK, Calif., Dec. 3, 2019 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced preliminary results from patients with transfusion-dependent (TD) beta-thalassemia in the ongoing TRANSCEND Phase 2 open-label study of PTG-300. Dose-related drug exposure and reductions from baseline serum iron and transferrin saturation (TSAT) levels were observed,

SAN FRANCISCO, Dec. 3, 2019 /PRNewswire/ -- Carrum Health, the first cloud-based platform connecting employers and employees with Centers of Excellence (COEs) for surgical procedures, to

PRINCETON, N.J., Dec. 3, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today it has completed patient enrollment in its Phase 3 "Fluorescent Light Activated